ArticleNPJ breast cancer2023

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.

Anthony D Elias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.